{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T08:06:17Z","timestamp":1783757177694,"version":"3.55.0"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35CA231996"],"award-info":[{"award-number":["R35CA231996"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA214170"],"award-info":[{"award-number":["U01CA214170"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.neo.2023.100910","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T01:20:30Z","timestamp":1685496030000},"page":"100910","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Genomics driven precision oncology in advanced biliary tract cancer improves survival"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8696-3400","authenticated-orcid":false,"given":"Chandan","family":"Kumar-Sinha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8441-7732","authenticated-orcid":false,"given":"Pankaj","family":"Vats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan R.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Gunchick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Mi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5356-9685","authenticated-orcid":false,"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Rabban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8743-7480","authenticated-orcid":false,"given":"Sunita","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6642-0468","authenticated-orcid":false,"given":"Rahul","family":"Mannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M.","family":"Zalupski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arul M.","family":"Chinnaiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1892-1548","authenticated-orcid":false,"given":"Vaibhav","family":"Sahai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neo.2023.100910_bib0001","first-page":"e3962","article-title":"Incidence of cholangiocarcinoma in the USA from 2001 to 2015: a US cancer statistics analysis of 50 states","volume":"11","author":"Patel","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.neo.2023.100910_bib0002","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12876-016-0527-z","article-title":"Increasing mortality in the United States from cholangiocarcinoma: an analysis of the national center for health statistics database","volume":"16","author":"Yao","year":"2016","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.neo.2023.100910_bib0003","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.neo.2023.100910_bib0004","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.3277","article-title":"Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma: a phase 2 clinical trial","author":"Sahai","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.neo.2023.100910_bib0005","first-page":"395","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"4","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2023.100910_bib0006","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1007\/s11605-007-0282-0","article-title":"Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis","volume":"11","author":"Nathan","year":"2007","journal-title":"J. Gastrointest. Surg."},{"key":"10.1016\/j.neo.2023.100910_bib0007","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1053\/j.gastro.2013.01.001","article-title":"Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes","volume":"144","author":"Sia","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.neo.2023.100910_bib0008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115383","article-title":"Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications","volume":"9","author":"Churi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neo.2023.100910_bib0009","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: Utility of next-generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.neo.2023.100910_bib0010","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/ng.2806","article-title":"Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers","volume":"45","author":"Chan-On","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neo.2023.100910_bib0011","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.18632\/oncotarget.1943","article-title":"Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups","volume":"5","author":"Simbolo","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.neo.2023.100910_bib0012","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of targetable FGFR gene fusions in diverse cancers","volume":"3","author":"Wu","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.neo.2023.100910_bib0013","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1016\/j.celrep.2017.06.008","article-title":"Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles","volume":"19","author":"Farshidfar","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.neo.2023.100910_bib0014","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2020.03.008","article-title":"Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma","volume":"73","author":"Montal","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.neo.2023.100910_bib0015","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/ng.2813","article-title":"Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas","volume":"45","author":"Jiao","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neo.2023.100910_bib0016","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.neo.2023.100910_bib0017","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2023.100910_bib0018","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS19-OT2-07-01","article-title":"Abstract OT2-07-01: a phase 2 study of futibatinib (TAS-120) in metastatic breast cancers harboring fibroblast growth factor receptor (<em>FGFR<\/em>) amplifications (FOENIX-MBC2)","volume":"80","author":"Turner","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.neo.2023.100910_bib0019","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.neo.2023.100910_bib0020","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.4_suppl.187","article-title":"Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E\u2013mutated biliary tract cancer (BTC): a cohort of the ROAR basket trial","volume":"37","author":"Wainberg","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2023.100910_bib0021","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-015-0155-z","article-title":"HER2\/neu-directed therapy for biliary tract cancer","volume":"8","author":"Javle","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.neo.2023.100910_bib0022","article-title":"SHR-1210 plus GEMOX as first line treatment in biliary tract cancer: results from a single-arm exploratory study","volume":"37","author":"Chen","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2023.100910_bib0023","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.4582","article-title":"A multicenter randomized phase II study of nivolumab in combination with gemcitabine\/cisplatin or ipilimumab as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-01)","volume":"38","author":"Sahai","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2023.100910_bib0024","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2468-1253(19)30086-X","article-title":"Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study","volume":"4","author":"Ueno","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.neo.2023.100910_bib0025","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.4520","article-title":"Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) \u00b1 tremelimumab (T) and gemcitabine\/cisplatin (GemCis) in chemo-na\u00efve advanced biliary tract cancer (aBTC)","volume":"38","author":"Oh","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2023.100910_bib0026","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.4079","article-title":"Pembrolizumab (pembro) for advanced biliary adenocarcinoma: results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies","volume":"37","author":"Bang","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2023.100910_bib0027","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.4_suppl.336","article-title":"Combined immune checkpoint inhibition (ICI) with tremelimumab and durvalumab in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinomas (BTC)","volume":"37","author":"Floudas","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2023.100910_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2020.0930","article-title":"A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer","volume":"6","author":"Kim","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.neo.2023.100910_bib0029","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.4082","article-title":"Efficacy and safety of pembrolizumab in patients with PD-L1 positive advanced biliary tract cancer (BTC): a prospective cohort study","volume":"37","author":"Kang","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2023.100910_bib0030","article-title":"Combination immunotherapy with ipilimumab and nivolumab in patients with advanced biliary tract cancers","volume":"38","author":"Klein","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2023.100910_bib0031","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cell.2015.06.053","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"162","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.neo.2023.100910_bib0032","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nature23306","article-title":"Integrative clinical genomics of metastatic cancer","volume":"548","author":"Robinson","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.neo.2023.100910_bib0033","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jama.2015.10080","article-title":"Integrative clinical sequencing in the management of refractory or relapsed cancer in youth","volume":"314","author":"Mody","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.neo.2023.100910_bib0034","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003161","article-title":"Personalized oncology through integrative high-throughput sequencing: a pilot study","volume":"3","author":"Roychowdhury","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neo.2023.100910_bib0035","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.cell.2018.04.034","article-title":"Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer","volume":"173","author":"Wu","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.neo.2023.100910_bib0036","article-title":"<strong>FusionCatcher<\/strong>\u2013 a tool for finding somatic fusion genes in paired-end RNA-sequencing data","author":"Nicorici","year":"2014","journal-title":"bioRxiv"},{"key":"10.1016\/j.neo.2023.100910_bib0037","unstructured":"Arriba. We used Arriba https:\/\/github.com\/suhrig\/arriba\/ to detect gene fusions from RNA-Seq data."},{"key":"10.1016\/j.neo.2023.100910_bib0038","article-title":"YAP1-MAML2-rearranged poroid squamous cell carcinoma (squamoid porocarcinoma) presenting as a primary parotid gland tumor","author":"Agaimy","year":"2020","journal-title":"Head Neck Pathol."},{"key":"10.1016\/j.neo.2023.100910_bib0039","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41379-019-0382-x","article-title":"Metaplastic thymoma: a distinctive thymic neoplasm characterized by YAP1-MAML2 gene fusions","volume":"33","author":"Vivero","year":"2020","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.neo.2023.100910_bib0040","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1038\/s41467-019-09940-1","article-title":"Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening","volume":"10","author":"Picco","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neo.2023.100910_bib0041","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1101\/gr.156224.113","article-title":"Discovery of recurrent structural variants in nasopharyngeal carcinoma","volume":"24","author":"Valouev","year":"2014","journal-title":"Genome Res."},{"key":"10.1016\/j.neo.2023.100910_bib0042","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/ng1083","article-title":"t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway","volume":"33","author":"Tonon","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neo.2023.100910_bib0043","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1038\/sj.emboj.7600719","article-title":"Transforming activity of MECT1-MAML2 fusion oncoprotein is mediated by constitutive CREB activation","volume":"24","author":"Wu","year":"2005","journal-title":"EMBO J."},{"key":"10.1016\/j.neo.2023.100910_bib0044","doi-asserted-by":"crossref","DOI":"10.1038\/nature23291","article-title":"Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS","author":"Yao","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.neo.2023.100910_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00124","article-title":"Palbociclib in patients with pancreatic and biliary cancer with CDKN2A alterations: results from the targeted agent and profiling utilization registry study","author":"Baghdadi","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.neo.2023.100910_bib0046","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"key":"10.1016\/j.neo.2023.100910_bib0047","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention","author":"Lowery","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2023.100910_bib0048","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000682","article-title":"Molecular profile of BRCA-mutated biliary tract cancers","volume":"5","author":"Spizzo","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.neo.2023.100910_bib0049","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.neo.2023.100910_bib0050","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2023.100910_bib0051","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.neo.2023.100910_bib0052","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41467-017-00388-9","article-title":"BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers","volume":"8","author":"Maxwell","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neo.2023.100910_bib0053","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2023.100910_bib0054","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.4085","article-title":"Frequency of BRCA mutation in biliary tract cancer and its correlation with tumor mutational burden (TMB) and microsatellite instability (MSI)","volume":"37","author":"Spizzo","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2023.100910_bib0055","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.19.02931","article-title":"Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation","volume":"38","author":"O'Reilly","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2023.100910_bib0056","first-page":"155","article-title":"Targeting ataxia-telangiectasia mutated deficient malignancies with poly ADP ribose polymerase inhibitors","volume":"2","author":"Radhakrishnan","year":"2013","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.neo.2023.100910_bib0057","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal2463","article-title":"2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity","volume":"9","author":"Sulkowski","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neo.2023.100910_bib0058","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.1309085110","article-title":"Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair","volume":"111","author":"Yu","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.neo.2023.100910_bib0059","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1038\/sj.emboj.7601291","article-title":"Mammalian SWI\/SNF complexes facilitate DNA double-strand break repair by promoting gamma-H2AX induction","volume":"25","author":"Park","year":"2006","journal-title":"EMBO J."},{"key":"10.1016\/j.neo.2023.100910_bib0060","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1517\/14728222.2015.1062879","article-title":"Potential therapeutic targets in ARID1A-mutated cancers","volume":"19","author":"Bitler","year":"2015","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.neo.2023.100910_bib0061","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41589-019-0294-6","article-title":"BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design","volume":"15","author":"Farnaby","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.neo.2023.100910_bib0062","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41591-018-0012-z","article-title":"ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade","volume":"24","author":"Shen","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.neo.2023.100910_bib0063","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1038\/s41467-018-05694-4","article-title":"Targeting AURKA-CDC25C axis to induce synthetic lethality in ARID1A-deficient colorectal cancer cells","volume":"9","author":"Wu","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neo.2023.100910_bib0064","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cell.2013.03.004","article-title":"Influence of metabolism on epigenetics and disease","volume":"153","author":"Kaelin","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.neo.2023.100910_bib0065","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1038\/onc.2012.315","article-title":"Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas","volume":"32","author":"Wang","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.neo.2023.100910_bib0066","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz394.027","article-title":"ClarIDHy: a global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation","volume":"30","author":"Abou-Alfa","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.neo.2023.100910_bib0067","doi-asserted-by":"crossref","unstructured":"Dinardo C.D., Stein A.S., Stein E.M., et\u00a0al. Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML). 2019;37:7011\u20137011.","DOI":"10.1200\/JCO.2019.37.15_suppl.7011"},{"key":"10.1016\/j.neo.2023.100910_bib0068","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.3390\/ijms20112679","article-title":"IDH1(R132H) Causes Resistance to HDAC Inhibitors by Increasing NANOG in Glioblastoma Cells","volume":"20","author":"Kim","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neo.2023.100910_bib0069","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V130.Suppl_1.639.639","article-title":"Mutant isocitrate dehydrogenase (mIDH) inhibitors, enasidenib or ivosidenib, in combination with azacitidine (AZA): preliminary results of a phase 1b\/2 study in patients with newly diagnosed acute myeloid leukemia (AML)","volume":"130","author":"DiNardo","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.neo.2023.100910_bib0070","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.neo.2023.100910_bib0071","doi-asserted-by":"crossref","first-page":"58007","DOI":"10.18632\/oncotarget.11157","article-title":"Therapeutic implication of HER2 in advanced biliary tract cancer","volume":"7","author":"Nam","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.neo.2023.100910_bib0072","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-015-0155-z","article-title":"HER2\/neu-directed therapy for biliary tract cancer","volume":"8","author":"Javle","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.neo.2023.100910_bib0073","article-title":"Safety and efficacy of pyrotinib in patients with NSCLC and other advanced solid tumors with activating HER2 alterations: A phase I basket trial","volume":"38","author":"Li","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2023.100910_bib0074","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/j.jtho.2019.06.027","article-title":"SWOG S1400C (NCT02154490)-a phase II study of palbociclib for previously treated cell cycle gene alteration-positive patients with stage IV squamous cell lung cancer (lung-MAP substudy)","volume":"14","author":"Edelman","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.neo.2023.100910_bib0075","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz244.037","article-title":"475P - A phase IIa clinical trial combining ALRN-6924 and palbociclib for the treatment of patients with tumours harboring wild-type p53 and MDM2 amplification or MDM2\/CDK4 co-amplification","volume":"30","author":"Meric-Bernstam","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.neo.2023.100910_bib0076","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/annonc\/mdy539","article-title":"Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study","volume":"30","author":"Hong","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.neo.2023.100910_bib0077","doi-asserted-by":"crossref","first-page":"e881","DOI":"10.1634\/theoncologist.2019-0641","article-title":"Antitumor activity of larotrectinib in esophageal carcinoma with NTRK gene amplification","volume":"25","author":"Hempel","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.neo.2023.100910_bib0078","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2018.01.021","article-title":"Systematic functional annotation of somatic mutations in cancer","volume":"33","author":"Ng","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.neo.2023.100910_bib0079","doi-asserted-by":"crossref","first-page":"6696","DOI":"10.1158\/1078-0432.CCR-13-1746","article-title":"BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition","volume":"19","author":"Hutchinson","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2023.100910_bib0080","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/MOG.0000000000000171","article-title":"Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma","volume":"31","author":"Borad","year":"2015","journal-title":"Curr. Opin. Gastroenterol."},{"key":"10.1016\/j.neo.2023.100910_bib0081","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.neo.2023.100910_bib0082","article-title":"Blocking CD73 can shrink pancreatic tumors","volume":"11","year":"2021","journal-title":"Cancer Discov."}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558623000350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558623000350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:12:28Z","timestamp":1761484348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558623000350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":82,"alternative-id":["S1476558623000350"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2023.100910","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomics driven precision oncology in advanced biliary tract cancer improves survival","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2023.100910","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100910"}}